Every GLP-1 Drug Label, Including Ozempic and Zepbound, Must Warn of Rare Sudden Vision Loss in One Eye

The FDA is requiring all GLP-1 drug labels to warn of a potential increased risk of rare eye condition NAION, while advising patients not to stop treatment without medical guidance.